New Generation Biofuels CEO to Present at the Rodman & Renshaw Annual Global Investment ...(condition and are based largely on ourcu...)

Date:11/7/2008

condition and are based largely on our current beliefs and expectations. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results expressed or implied by such forward-looking statements. The risks and uncertainties related to our business include all the risks attendant a development stage business in the volatile energy industry, including, without limitation, the risks set forth under the caption "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2008.

CONTACT:

David Gillespie, President & CEO

New Generation Biofuels, Inc.

713-973-5720

Rob Schatz

Wolfe Axelrod Weinberger Associates, LLC

212-370-4500

'/>"/>

SOURCE New Generation Biofuels Holdings, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related biology technology :

1. Osteotechs Next Generation Grafting Material, MagniFuse(TM) Bone Graft, a Breakthrough in Bone Regeneration; MagniFuse(TM) Bone Graft seeks to redefine the standard of care in the U.S. bone graft substitute market estimated to be in excess of $1.2 billio
2. Osteotech Receives FDA Clearance for its Next Generation Grafting Material
3. Pioneer(R) Surgical Technology Announces Market Release of FortrOss(TM), a Next Generation Bone Void Filler
4. Spring Point Project Welcomes Second Generation Medical-Grade Piglets
5. CorMatrix Cardiovascular to Present Data on Its Next Generation ECM Technology(TM) at Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference in Washington, D.C.
6. Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent
7. Targeting Metastatic Cancer From the Inside: Epeius Biotech Reveals a New Generation of Tools for Medical Gene Delivery
8. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
9. Oklahoma CyberKnife Center Cuts Treatment Time in Half With Next Generation CyberKnife Technology
10. Introducing the next generation of chemical reactors
11. First Coast Oncology to Offer Next Generation Proton Therapy